Hip Fracture in Cauca. Cohort Study
Launched by UNIVERSIDAD DEL CAUCA · Jan 2, 2020
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
Hip fracture is an important cause of disability, functional risk and death in the adult population, being more significant in the elderly, it also entails high costs for the health system. Although it is usually rare before the sixth decade of life and is very rare in young people, patients who present a hip fracture functional risk can be very important, reaching prostration in up to 8% of cases when Your surgical management is delayed. It is known that the time elapsed between diagnosis and treatment that affects the survival of patients, because every two days of surgical waiting double...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults (male or female) ≥ 18 years of age
- • Diagnosis of femoral fracture
- • Receiving surgical treatment
- Exclusion Criteria:
- • Patients with cognitive disorders that prevent interrogation and assessment of quality of life.
- • Patients referred to another institution for surgery.
- • Patient who decides to voluntarily withdraw from the investigation.
About Universidad Del Cauca
Universidad del Cauca is a distinguished academic institution located in Colombia, recognized for its commitment to advancing medical research and clinical trials. With a focus on enhancing public health outcomes, the university conducts rigorous studies that aim to address critical healthcare challenges. Leveraging its robust network of researchers, healthcare professionals, and state-of-the-art facilities, Universidad del Cauca fosters an environment of innovation and collaboration, ensuring adherence to ethical standards and regulatory compliance in all its clinical research endeavors. Through its initiatives, the university strives to contribute to the global body of medical knowledge and improve patient care in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Popayán, Cauca, Colombia
Patients applied
Trial Officials
Angela M Merchán Galvis, MD, MSc
Principal Investigator
Universidad del Cauca
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials